Lisata Therapeutics, Inc. (LSTA) — AI Stock Analysis
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing cellular therapies. Their pipeline includes HONEDRA, XOWNA, and CLBS201, targeting critical limb ischemia, coronary microvascular dysfunction, and chronic kidney disease.
Company Overview
TL;DR:
About LSTA
Investment Thesis
Industry Context
Growth Opportunities
- Expansion of HONEDRA's clinical applications: Leveraging the SAKIGAKE designation, Lisata can explore additional indications for HONEDRA beyond critical limb ischemia. The market for peripheral artery disease (PAD), which includes CLI, is estimated to reach billions of dollars, providing a significant growth opportunity. Timeline: Ongoing clinical trials with potential for expansion within the next 2-3 years.
- Advancement of XOWNA for coronary microvascular dysfunction: Successful completion of Phase IIb trials for XOWNA could unlock a substantial market in coronary microvascular dysfunction (CMVD). The prevalence of CMVD is high, particularly among women, creating a significant unmet medical need. Timeline: Phase IIb trial results expected within the next 1-2 years, with potential for Phase III initiation thereafter.
- Development and commercialization of CLBS201 for chronic kidney disease: CLBS201 represents a potential breakthrough in treating chronic kidney disease (CKD) in pre-dialysis patients. The global CKD market is substantial and growing, driven by the aging population and increasing prevalence of diabetes and hypertension. Timeline: Continued development and potential partnerships for commercialization within the next 3-5 years.
- Strategic partnerships and collaborations: Lisata can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its pipeline assets. These partnerships can provide access to funding, expertise, and established distribution networks. Timeline: Ongoing efforts with potential for partnerships within the next 1-2 years.
- Pipeline expansion through acquisitions or in-licensing: Lisata can expand its pipeline by acquiring or in-licensing promising new cellular therapies or related technologies. This would diversify its portfolio and reduce reliance on its current lead candidates. Timeline: Ongoing evaluation of potential acquisition or in-licensing opportunities.
- Market capitalization of $0.04 billion, indicating potential for growth if clinical trials are successful.
- Gross margin of 100.0%, reflecting strong potential pricing power for its therapies upon commercialization.
- HONEDRA received SAKIGAKE designation, highlighting its potential in treating critical limb ischemia.
- Phase II clinical trials underway for HONEDRA (critical limb ischemia) and XOWNA (coronary microvascular dysfunction), representing key milestones.
- Beta of 1.27, suggesting higher volatility compared to the overall market.
What They Do
- Develop cellular therapies for reversing disease.
- Promote regeneration of damaged tissue.
- Focus on critical limb ischemia (CLI) treatment with HONEDRA.
- Develop XOWNA for coronary microvascular dysfunction (CMVD).
- Create CLBS201, a CD34+ cell therapy for chronic kidney disease (CKD).
- Conduct Phase II clinical trials for HONEDRA and XOWNA.
- Target pre-dialysis patients with CLBS201.
Business Model
- Develop and patent novel cellular therapies.
- Conduct clinical trials to demonstrate safety and efficacy.
- Seek regulatory approvals for commercialization.
- Potentially partner with larger pharmaceutical companies for distribution.
- Generate revenue through sales of approved therapies.
- Patients with critical limb ischemia (CLI).
- Patients with coronary microvascular dysfunction (CMVD).
- Pre-dialysis patients with chronic kidney disease (CKD).
- Healthcare providers and hospitals.
- Potential pharmaceutical partners.
- Proprietary cellular therapy technologies.
- SAKIGAKE designation for HONEDRA, providing regulatory advantages.
- Clinical trial data demonstrating efficacy and safety.
- Strong intellectual property portfolio.
- Expertise in cellular therapy development and manufacturing.
Catalysts
- Upcoming: Phase II clinical trial results for HONEDRA in critical limb ischemia.
- Upcoming: Phase IIb clinical trial results for XOWNA in coronary microvascular dysfunction.
- Ongoing: Potential for strategic partnerships to fund development and commercialization.
- Ongoing: Expansion of pipeline through acquisitions or in-licensing.
Risks
- Potential: Clinical trial failures for HONEDRA, XOWNA, or CLBS201.
- Potential: Regulatory delays or non-approval of therapies.
- Ongoing: Competition from larger pharmaceutical companies with greater resources.
- Ongoing: Difficulty in securing additional funding to support operations.
- Ongoing: Dependence on a limited number of product candidates.
Strengths
- Proprietary cellular therapy platform.
- SAKIGAKE designation for HONEDRA.
- Targeted approach to unmet medical needs.
- Experienced management team.
Weaknesses
- Clinical-stage company with no approved products.
- Reliance on successful clinical trial outcomes.
- Limited financial resources.
- High cash burn rate.
Opportunities
- Positive clinical trial results driving valuation.
- Strategic partnerships for development and commercialization.
- Expansion into new therapeutic areas.
- Acquisition of complementary technologies.
Threats
- Clinical trial failures.
- Regulatory hurdles and delays.
- Competition from established pharmaceutical companies.
- Difficulty in securing funding.
Competitors & Peers
- CASI Pharmaceuticals, Inc. — Focuses on developing and commercializing innovative therapeutics and pharmaceutical products in China. — (CASI)
- Celgene Corporation — Develops therapies for cancer and inflammatory disorders (acquired by Bristol Myers Squibb). — (CLGN)
- Clearside Biomedical, Inc. — Develops therapies for retinal diseases. — (CLSD)
- Enlivex Therapeutics Ltd. — Develops immunotherapy treatments for organ dysfunction and immune system imbalances. — (ENLV)
- KalVista Pharmaceuticals, Inc. — Develops oral therapies for hereditary angioedema and other plasma kallikrein-mediated diseases. — (KLTO)
Key Metrics
- Price: $5.02 (+0.20%)
- Market Cap: $46
- Volume: NaN
- MoonshotScore: 58/100
Analyst Price Target
- Analyst Consensus Target: $9.50
- Current Price: $5.02
- Implied Upside: +89.2%
Company Profile
- CEO: David J. Mazzo
- Headquarters: Basking Ridge, NJ, US
- Employees: 26
- Founded: 1999
AI Insight
常见问题
What does Lisata Therapeutics, Inc. do?
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cellular therapies to treat vascular and kidney diseases. Their lead product candidates include HONEDRA for critical limb ischemia, XOWNA for coronary microvascular dysfunction, and CLBS201 for chronic kidney disease. The company aims to reverse disease progression and promote tissue regeneration through innovative cellular therapeutics. Lisata's business model involves developing and patenting novel therapies, conducting clinical trials, and seeking regulatory approvals for commercialization, potentially partnering with larger pharmaceutical companies for distribution.
Is LSTA stock a good buy?
LSTA stock presents a speculative investment opportunity with high potential upside and significant risks. The company's pipeline of cellular therapies targets unmet medical needs, and positive clinical trial results could drive substantial valuation increases. However, as a clinical-stage company with a negative P/E ratio of -2.23 and a profit margin of -1704.9%, LSTA is heavily reliant on successful clinical trial outcomes and securing additional funding. Investors should carefully consider their risk tolerance and conduct thorough due diligence before investing in LSTA.
What are the main risks for LSTA?
The main risks for Lisata Therapeutics include clinical trial failures, regulatory hurdles, competition, and funding challenges. Clinical trial failures for any of its lead product candidates (HONEDRA, XOWNA, or CLBS201) would significantly impact the company's valuation. Regulatory delays or non-approval of therapies could also hinder commercialization efforts. Lisata faces competition from larger pharmaceutical companies with greater resources. Securing additional funding to support operations is crucial, and any difficulty in raising capital could jeopardize the company's development plans.
Is LSTA a good investment right now?
Use the AI score and analyst targets on this page to evaluate Lisata Therapeutics, Inc. (LSTA). Our analysis considers fundamentals, technicals, and market sentiment to help you decide.
What is the MoonshotScore for LSTA?
The MoonshotScore is a proprietary 0-100 AI rating that evaluates Lisata Therapeutics, Inc. across multiple dimensions including financial health, growth trajectory, and risk factors.
Where can I find LSTA financial statements?
Lisata Therapeutics, Inc. financial data including revenue, earnings, and balance sheet metrics are available in the Financials tab on this page, sourced from institutional-grade data providers.
What do analysts say about LSTA?
Analyst consensus targets and ratings for Lisata Therapeutics, Inc. are shown in the analysis section. These are aggregated from major Wall Street firms and updated regularly.
How volatile is LSTA stock?
Check the beta and historical price range on this page to assess Lisata Therapeutics, Inc.'s volatility relative to the broader market.